Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., priced an underwritten registered direct offering of 18 million common shares at $1.00 per share, generating approximately $18 million in gross proceeds. The offering is anchored by a $15 million investment from a fundamental institutional investor and is expected to close on or about April 24 2026.
The capital raise is intended to strengthen Lucid’s balance sheet and provide working capital and general corporate funds. The company’s cash burn has been significant, with negative free cash flow of $46.68 million over the last twelve months, and the infusion is expected to extend the runway for development and commercialization of its EsoGuard esophageal DNA test and EsoCheck cell‑collection device.
Lucid’s market capitalization stands at roughly $223 million and its revenue for the most recent fiscal year was $4.71 million. The funding will support ongoing clinical and regulatory milestones for the EsoGuard platform, which is positioned as the first commercially available tool for early detection of esophageal precancer in patients with gastro‑esophageal reflux disease.
PAVmed’s strategy of maintaining a lean shared‑services platform while allowing subsidiaries to raise capital independently is reflected in this transaction. The parent company has been restructuring its balance sheet, eliminating convertible securities and strengthening its capital base, thereby enabling Lucid to secure financing without diluting PAVmed’s ownership structure.
Investors have expressed concern about shareholder dilution, which has tempered the market reaction to the announcement. The offering’s price of $1.00 per share is below the company’s current trading level, underscoring the dilution impact that investors are weighing against the benefits of the additional capital.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.